Entrada Therapeutics (NASDAQ:TRDA) is a biotechnology firm focused on the development of innovative therapies. The company specializes in creating drugs designed to engage intracellular targets, aiming to treat a broad range of diseases, including neuromuscular conditions and other serious ailments. Entrada Therapeutics is leveraging its proprietary platform to advance a portfolio of oligonucleotide and peptide therapeutics aimed at addressing unmet medical needs. With a commitment to science and patient care driving its operations, the firm is dedicated to pushing the boundaries of medicine to improve the lives of patients worldwide.